moomoo ID:NaN
Log Out
Log in to access Online Inquiry

Biomea Fusion Reports New Study Data From Two Preclinical Rat Models of Diabetes

MT Newswires ·  {{timeTz}}

11:59 AM EDT, 09/22/2022 (MT Newswires) -- Biomea Fusion (BMEA) said Thursday that new study data show that its drug BMF-219 is able to improve pancreatic beta cell area and function in two preclinical rat models of diabetes during the dosing period.

Both glycemic and lipemic control were maintained in the groups after the dosing period ended, according to the company.

The treatment led to a sustained increase in beta cell area and function in one of the rat models, compared with rats treated with vehicle or active control pioglitazone. BMF-219 also showed a recovery of beta-cell activity in the second rat model after 16 days of treatment, compared with rats treated with vehicle control or pioglitazone, Biomea said.

The treatment also showed an increase in beta cell mass in ex-vivo experiments with human donor islets, according to a statement.

The company said it is on track to file an investigational new drug application to explore the use of BMF-219 in type-2 diabetes in the second half of 2022.

Biomea shares were down 0.6% in recent trading.

Price: 10.99, Change: -0.17, Percent Change: -1.52

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.